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INTRODUCTION
In the experiments described here, a physiological measurement is made
while photochemical procedures are employed to alter (a) the concentra-
tion of a ligand near membranes or proteins or (b) the structure of the
ligand-receptor complexes. Because photochemical reactions often pro-
vide the quickest way to produce such chemical perturbations, we em-
phasize the kinetic information that such experiments have yielded. This
information requires a suitably rapid physiological measurement, usually
an electrical or optical one. The results often complement hose obtained
with other kinds of kinetic investigation (iontophoretic application of
drugs, stopped-flow mixing, temperature jump, etc). Pharmacological
manipulations with light flashes are especially useful for biological sys-
tems that cannot be flowed, for instance membranes under electrophysio-
logical investigation or solutions at very low temperatures.
In a conceptual sense, this chapter could treat flash-photolysis investi-
gations of heme proteins; but the topic has recently been reviewed
authoritatively (84). This review does not concern photoaffinity labeling
(28) or studies on fluorescence recovery after photobleaehing.
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152 LESTER & NERBONNE
PHOTOCHEMICAL STRATEGIES
General Constraints
For pharmacological experiments with light flashes, one requires a photo-
sensitive molecule that satisfies several criteria.
1. The compound must be soluble in aqueous solutions of moderately
high ionic strength.
2. The photochemical reaction must also proceed in this medium.
3. The photochemical reaction should take place instantaneously with
respect to the time scale (usually milliseconds to seconds) of the
physiological phenomenon being studied, without the formation of
reactive intermediates or active by-products.
4. The photoproduct should be stable (thermally and solvolytically) 
the same time scale so that the flash produces a true "concentration
jump" of active molecules. (On the other hand, for some studies it
may be quite useful to generate a "concentration pulse" if the time
course of the pulse is accurately known.)
5. The photochemical reaction should proceed at wavelengths long
enough to cause no significant damage to cellular components. A
tentative guideline for this criterion would be X > 300 nm, although
an efficient photochemical strategy might produce acceptably low
damage for wavelengths down to about 250 nm.
6. The efficiency per incident photon should place the reaction within
reach of flashlamps and collimated (rather than focused) pulsed
lasers. A tentative guideline for this requirement is that the extinction
coefficient, e, times the quantum yield, ~, for the reaction should
exceed about 500.
7. Both the precursor and the photoproduct should have simple, well-
characterized equilibrium effects on the physiological system; there
should be no complicating interactions with proteins or membranes.
These combined constraints are known to be satisfied by only a few of
the many available photochemical processes and photosensitive mole-
cules.
Photoisomerization
CIS-TRANS PHOTOISOMERIZATION OF AZOBENZI~NES Azobenzene and
many of its derivatives can exist in both cis and trans configurations with
respect to the axis of the azo nitrogens.
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t[on$
The trans configuration is planar; but in the cis configuration, steric
hindrance between the two ortho hydrogens forces the benzene rings into
two planes skewed at 53° (4). As a result, the two configurations differ 
many physical properties such as thermochemistry, dipole moment, and
absorption spectra (92). It is not surprising that certain azobenzene
derivatives display different pharmacological properties in the two iso-
meric configurations, as described in more detail below.
Some photoisomerizable azobenzene derivatives have photophysical
properties well studied for kinetic experiments on membranes and pro-
teins. The cis -~ trans and trans -~ cis photoisomerizations are produced by
light of wavelengths 410-450 nm and 300-350 nm, respectively. The
photoisomerizations occur within a microsecond after absorption of a
photon (94) and with a high quantum yield. Photoisomerization is the
only result of photon absorption: there are no long-lived excited states,
reactive intermediates, or competing photoreactions. The cis and trans
configurations are thermally stable for at least several seconds and, with
most of the molecules, for several days. These photoisomerizable com-
pounds have the drawback that flashes lead to a photostationary mixture
of the cis and trans configurations, rather than to pure solutions of one or
the other configuration. However, the composition of the photostationary
state and the rate of approach can be determined experimentally. For a
given compound, the composition of the photostationary state depends
on the wave-length of irradiation, ?~. If the cis and trans isomers have
molar absorption coefficients ec, t(A) respectively, and quantum yields
qc, t(h) for photoisomerization, then the mole fracdon of cis isomers in
the photostationary state is et~t/(et~ t + ec¢c). For the molecule we have
studied in most detail, Bis-Q, the highest percentage of cis, 94-96%,
is produced by 3"38-341 nm light (35, 79); and 420-440 nm light
produces 66% trans isomers. In dilute solutions, the photostationary
state is approached exponentially with the number of flashes; the
intensity I(A, t’) of the flash (where t" is time) determines the "rate"
constant Kc + Kt (in units of flash-l), where Kc.t 
fx ft,I(h, t’)ec, t(A )e~c,,(?~ ) dr’ For a weakflashof intensity dKc, t, the
fraction of molecules that undergo photoisomerization is dKc, r Further-
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154 LESTER & NERBONNE
more, the percentage of cis in the photostationary state is given by
Kt/(Kc + Kt). The parameters Kc,t can be determined, for a particular
flash intensity and a particular compound, by spectral measurements
during the approach to the photostationary state. Thus it is not necessary
to know I, e, and ¢ individually. With flashlamps and pulsed lasers,
values of about one flash- l can now be achieved for both Kc and Kt (65,
79, 81), so that a single flash converts the solution most of the way to the
photostationary state.
The photoisomerization properties are not expected to be sensitive to
any solvent or binding conditions likely to occur in or near biological
membranes (19, 27, 118). These expectations have recently been partially
verified with spectral measurements on azobenzene molecules that were
covalently bound to bovine serum albumin (95) or to detergent-solubilized
membrane proteins (94). Laser flashes photoisomerized these bound
molecules with Kc,t values identical to those found with the unbound
molecules in aqueous solution.
More activeCompound Action configuration
N+(CH3)3
QBr
[~ = N÷(CH3}3
CH2Br
I N (CH3).~
N*(CH3)3 0
H II
/~N--C--O.. CHz
EW-I N:N
~Hz[~ N÷(CH3)3
Reversibly bound irons
ogonist
Tethered agonisl trans
Competitive antagonist c/~
Open- channel blocker
[local anesthelic)
Figure 1 Photoisomerizable cholinergic compounds designed and synthesized by N. H.
Wassermann and B. F. Erlanger.
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LIGHT-FLASH PHARMACOLOGY 155
In summary, the azobenzene derivatives in Figure 1 fulfill the require-
ments for calibrated "concentration jumps" that are instantaneous on the
time scale of channel gating in biological membranes.
Photoisomerizable azobenzene groups have been incorporated into
crown ethers. The two isomers extract alkali metal cations into liquid
membranes to differing extents (96). Such molecules also might provide 
means for controlling the permeability of biological membranes.
OTHER PHOTOISOMERIZABLE COMPOUNDS Some 2,2’ stilbene disulf-
onates block the anion exchange system of erythrocyte membranes (15,
23); and the cis and trans isomers have different potencies (39, 40, 97).
No measurements have been reported on modifications to anion flux
during photoisomerization of these compounds.
Cyanine, merocyanine, carbocyanine, and related dyes undergo several
types of photochemical reaction. In the best-studied photoisomerization
reaction, absorption of a photon by spiropyrans leads to C-O bond
cleavage, producing a merocyanine (102). Other possible photoreactions
include oxidation-reduction, excimer, and long-lived triplet formation.
The resulting charge rearrangements lead to photovoltages in lipid bi-
layer membranes exposed to certain dyes (11, 35, 50, 51, 106, 107).
Experiments are also underway to employ these or similar effects to
photostimulate living cells (44; A. Grinvald, personal communication).
Photochemical Cleavage of Blocking Groups
Several small aromatic groups can be cleaved with light of wavelength
greater than 300 nm in aqueous solution (reviewed in 87). The most
common scheme exploits the light-induced internal oxidation-reduction
reaction in nitroaromatics with a benzylic hydrogen ortho to the nitro
group (7, 78). The o-nitrobenzyl moiety has been removed photochemi-
cally from esters to form carboxylate groups (12, 86).
R
hv H+O--CH ~ RCO~ + + OC
The phosphodiester or phosphotriester is similarly cleaved to form phos-
phates (56).
NOz NO
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156 LESTER & NERBONNE
The phosphodiester photolysis has been studied kinetically, as described
below; under some circumstances the phosphate is formed within milli-
seconds (75). In the simplest o-nitrobenzyl derivative, R’= H, and the
photolysis results in a nitroso aldehyde byproduct (36, 37). This aldehyde
apparently causes few problems at micromolar concentrations (37); but
at higher concentrations it participates in further reactions that vitiate the
compounds’ usefulness. These problems can be avoided by derivatizing
the benzylic carbon, so that the less reactive ketone is formed instead.
Thus the o-nitrobenzyl group has been photoremoved from compounds
in which R’ is a phenyl (12), methyl (53), or another o-nitrobenzyl group
(86).
In extensions of this technique, 2-nitrobenzyloxycarbonyl and 6-
nitroveratryloxycarbonyl derivatives of amino groups can be photolyzed
to yield the free amino groups (8, 12, 86).
NO2
CH~O -~-CH2-O-C--
CH~O
NO
CH.~O/’---" H
+ COz + H2NR
Because many neurotransmitters and local anesthetics contain amino
groups critical to their function, this reaction is of great potential interest.
o-Nitrobenzyl ethers have also been prepared and photolyzed to yield
hydroxyl groups in phenols (6), sugars (8, 116, 117), and nucleotides 
22, 83, 84). Both the amino and hydroxy groups can be photogenerated
in aqueous solution, but nothing is known about the speed of the
reactions.
The 5-bromo-7-nitroindolinyl moiety is another promising photo-
cleavable group, particularly because photosolvolysis proceeds with light
of wavelength 420 nm (as compared with 350 nm for the o-nitrobenzyl
group) (5, 43).
SYNAPTIC TRANSMITTERS
Studies on Nicotinic Acetylcholine Receptors
ELECTROPHYSIOLOGY Pharmacological manipulations with light flashes
complement several powerful electrophysiological methods for kinetic
studies on ion channel gating by nicotinic acetylcholine receptors [most
recently reviewed in (2)]. In all modem studies, the voltage-clamp tech-
nique is applied either to whole cells or to microscopic (~ 1/xm2) patches
of membrane (44a). Voltage-clamp currents are proportional to the
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LIGHT-FLASH PHARMACOLOGY 157
number of open channels in the membrane, with a temporal resolution of
several tens of microseconds in favorable cases, as the channel popula-
tion responds to forced or spontaneous perturbations. The available
perturbations may be summarized as follows.
1. The neurally evoked postsynaptic current is produced by an im-
pulse that propagates into the presynaptic nerve terminal. A brief but
concentrated pulse of acetylcholine is liberated into the synaptic cleft
between the presynaptic and postsynaptic cells. Acetylcholine binds to
receptors; channels open rapidly so that the current reaches, a peak
within ~200 /~s; and the transmitter is then efficiently hydrolyzed by
acetylcholinesterase as it dissociates from receptors. As a result, very few
channels open after the peak. Therefore the neurally evoked postsynaptic
current declines exponentially with a rate constant equal to that for
channel closing_ (2, 72, 73, 111).
2. The voltage-jump relaxation is performed in the presence of a
constant, externally applied agonist concentration. This experiment ex-
ploits the voltage sensitivity of the agonist-receptor interaction, so that
the voltage-clamp circuit is employed both to produce the perturbation
and to measure its consequences. Voltage-jump experiments give infor-
mation about both opening and closing rates.
3. In fluctuation analysis, all the stimulating parameters are kept
constant and one studies the fluctuations in voltage-clamp currents
produced by spontaneous deviations about equilibrium.
4. In favorable circumstances, one can resolve the step-like changes
associated with the opening and closing of individual channels (44a).
PHOTOCHEMISTRY Based on earlier studies with blockers of serine
esterases (16-18, 38, 54, 109), Erlanger and Wassermann designed and
synthesized a series of azobenzene derivatives that interact with nicotinic
acetylcholine receptors (Figure 1). These molecules have two crucial
properties: (a) they are photoisomerizable, as described above; (b) 
two configurations differ in their pharmacological properties.
THE AGONIST, BIS-Q At the nerve-muscle and nerve-electroplaque syn-
apses of several South American and African fishes, trans-Bis-Q acts as a
potent but typical nicotinic agonist at concentrations on the order of
10-7 M (13, 63, 65, 81, 113). At 10°C and a membrane potential of -75
mV, it interacts with acetylcholine receptors to open channels with a
conductance of 26 ps and a lifetime of 4 msec;~ both these values are
~Known rticotirdc agonists induce channels with roughly a tenfold range of durations
when tested under identical conditions. The actual duradon depends muldplicatively on
several conditions, such as temperature, membrane voltage, and synaptic vs extrasynaptic
location. Trans-Bis-Q and acetylcholine induce channels of relatively long duration.
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158 LESTER & NERBONNE
identical to those measured with acetylchohne itself under the same
conditions (113). The rate constant for opening increases with trans-Bis-Q
concentration (65, 81). The dose-response curve is sigmoid, with a Hill
slope very near 2 (93). The agonist-induced conductance can be blocked
by the competitive antagonist, tubocurarin¢ (63, 65), and by the "open-
channel blocker", QX-222 (65), and desensitizes with continued exposure
to Bis-Q.
Electroplaques from the giant Amazonian electric eel, Electrophorus
electricus, constitute a particularly suitable preparation for combined
electrophysiological and photochemical experiments on Bis-Q. The cis
configuration is less than 100 times as potent an agonist as the trans
configuration; indeed, any channels induced by solutions of nominally
pure cis isomer could be due to trace contamination by trans-Bis-Q. At
concentrations of 1 gM or less, cis-Bis-Q also shows no inhibitory action,
either as a competitive antagonist or as an "open-channel blocker." Thus
cis-Bis-Q apparently fails to bind to acetylcholine receptors. This situa-
tion made it possible to generate information from two unique types of
photochemical perturbation.
The first experiment is the photochemically-induced "concentration-
jump" of agonist. One begins with a solution of cis-Bis-Q and uses a flash
lamp or, more recently, a pulsed laser to produce a sudden step of
trans-Bis-Q concentration. A series of such experiments (59, 61, 67)
culminated in the observation that receptor channels begin to open
within 10 gs after the first agonist molecules appear near receptors. This
datum reduced (by about tenfold) the upper limit on the delay that the
agonist-receptor interaction contributes to the transmission of a nerve
impulse across a nicotinic synapse. It was hoped that the detailed time
course of such "concentration-jump relaxations" would yield new data
on agonist-receptor binding, conformational changes, or other events
leading to channel activation. An initial delay, in particular, could have
been of interest. However, thus far the concentration-jump relaxations
have been single exponential functions of time (63, 65, 81), like voltage-
jump relaxations and autocorrelation functions measured with Bis-Q and
other agonists. The exponential time course is maintained even at the
earliest times after the flash, within the resolution of the voltage-clamp
circuitry (50-100 gs) (M. S. Brodwick, R. E. Sheridan, and H. A. Lester,
unpublished).
A second type of photochemical perturbation with Bis-Q has, however,
produced uniquely interesting information. In this experiment, a flash
produces trans ~ cis photoisomerization of trans-Bis-Q molecules that are
bound to receptors with open channels. This photochemical perturbation
does not depend on a "concentration jump" of agonist near receptors; it
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LIGHT-FLASH PHARMACOLOGY 159
is instead a "molecular rearrangement" of the agonist-receptor complex
itself. Thus the experiment is analogous to flash-photolysis experiments
on liganded hemoproteins, with the difference that subsequent events are
monitored with electrophysiological rather than with optical techniques.
As a consequence of the trans -~ cis photoisomerization, receptors are no
longer occupied by agonist molecules; therefore channels close. The
resulting rate of channel closing is one to two orders of magnitude faster
than the rate of channel opening produced by the "concentration-jump"
described in the preceding paragraph (61, 81) and is, in fact, the fastest
known kinetic process at acetylcholine receptors. This signal has been
termed phase 1; and its speed allows its measurement uncomplicated by
slower processes.
Phase 1 has been analyzed for information on the temporal and
stoichiometric aspects of coupling between agonist binding and channel
activation (81, 93, 94). The theory is that each receptor’s channel remains
open if and only if n agonist molecules are present at the receptor’s
binding site. Thus the channel closes if any of the bound trans-Bis-Q
molecules are photoisomerized to the cis configuration. The photon cross
section for channel closing is therefore n times that for trans--, cis
photoisomerization. The experiments involved comparing the effects of
flashes on (a) the fraction of Bis-Q molecules that undergo trans-~ cis
photomerization (Kt, measured spectrally) and (b) the fraction of chan-
nels that close (measured electrophysiologically as the amplitude of phase
1). The ratio was n =2.06-+0.09 (mean -+ SEM). This result provides 
very direct confirmation of the concept that the open state of a receptor’s
channel is much more likely to be associated with the presence of tw9
bound agonist molecules than with a single bound agonist molecule. This
result also verifies that both receptor molecules are bound the entire time
the channel remains open. It can also be argued, albeit less directly, that
at least one agonist molecule leaves the receptor as the channel closes
(81).
Bis-Q is much less potent at the acetylcholine receptors of many other
teleost fishes (M. E. Krouse, M. M. Weinstock, H. A. Lester, unpublished
results), of elasmobranch fishes (60), and of reptiles (M. M. Weinstock,
unpublished), producing observable conductances at several tens of ~M.
Kinetic experiments with these less responsive preparations are com-
plicated by the fact that Bis-Q also exerts "open-channel blockade" at
such concentrations (3). At frog, rat, and mouse end plates, trans-Bis-Q
has no detectable potency as an agonist. Several agonists are known (for
instance deeamethonium) whose potency differs among nicotinic recep-
tors from various animals, but the species variations seen with Bis-Q are
probably the largest reported. The reasons are not known. Perhaps the
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160 LESTER & NERBONNE
azo double bond interacts strongly with only some receptors (110);
perhaps only some membranes are suitable environments for the trans-
Bis-Q molecule’s combination of large dipole moment accompanied by
hydrophobic regions (35).
THE TETHERED A~ONIST, QBr Silman & Karlin (98) designed and synthe-
sized agonists that can be covalently linked to the acetylcholine receptor
at a sulfhydryl group (formed by previous reduction with dithiothreitol)
near the binding site for agonists. These compounds, which have been
termed tethered agonists (65), produce a persistent activation of channels.
They offer two advantages for kinetic studies. (a) Tethered agonists
eliminate the first step in the agonist-receptor binding reaction, namely
the initial, diffusion-limited encounter with receptors. (b) Because the
unreacted molecules are washed out of the preparation after the tethering
reaction, there is no chance that they can also function as competitive
antagonists or "open-channel blockers." Their disadvantage is that, like
all known agonists, they eventually desensitize receptors, so that the
number of open channels decreases with time (31, 32). This shortcoming
is avoided by the photoisomerizable tethered agonist, QBr (13, 65; Figure
1). QBr is tethered to receptors in its active, trans configuration and can
then be photoisomerized to a predominantly cis mixture that neither
opens channels nor desensitizes them, until the moment of the voltage-
clamp test. This feature, in conjunction with advantage (b) above, may
render tethered QBr a more generally useful ligand than Bis-Q for studies
of nicotinic acetylcholine receptors. In addition to Electrophorus electro-
plaques, QBr has been tethered to the acetylcholine receptor of skate
electroplaques, where its properties resemble those seen with Electro-
phorus (H. A. Lester, M. E. Krouse, M. M. Weinstock, unpublished). 
expected for a tethered agonist, the QBr-induced conductance cannot be
blocked by the competitive antagonist, tubocurarine, but remains sensi-
tive to "open-channel blockers" such as QX-222. Also as expected, the
relaxation kinetics reveal that the channel opening rate is governed by an
intramolecular transition, rather than by a bimolecular process involving
free agonist molecules and membrane-bound receptors (65).
Apart from these expected differences, the channels opened by QBr
and other tethered agonists share many properties with those opened by
reversibly bound agonists (3 t, 32, 65). Channels fluctuate between open
and dosed states. Voltage-jump relaxations follow an exponential time
course; their analysis reveals that the rate constant for channel opening
does not depend on membrane voltage, whereas the rate constant for
closing depends on voltage to about the same extent as for reversibly
bound agonists. The actual magnitudes of these rate constants are ..about
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LIGHT-FLASH PHARMACOLOGY161
twice as great as those seen with 50 ~tM carbachol, a typical reversibly
bound agonist, and have the same sensitivity to temperature. As with
reversibly bound BisoQ, tethered QBr is an agonist in the trans configura-
tion but tethered cis-QBr does not open channels. These similarities all
suggest that the same rate-limiting step governs the opening and closing
of channels for both reversibly bound and tethered agonists. Therefore,
this step is probably not the initial, diffusion-limited encounter between
agonist and receptor molecules. Instead, the rate-limiting step is some
subsequent rearrangement or conformational change of the agonist-
receptor-channel complex, as discussed in detail by several authors (2, 42,
65, 72, 73).
With tethered QBr as with reversibly bound Bis-Q, uniquely interesting
information comes from experiments in which the agonist-induced con-
ductance is measured while flashes produce molecular rearrangements of
the agonist-receptor complex (65). Channels are opened by cis-~ trans
photoisomerizations and closed by trans ~ cis photoisomerizations; this
cycle can be repeated many times. The kinetics of the relaxations confirm
that one is dealing with intramolecular events, with no dependence on
free agonist molecules. The amplitudes of the conductance changes were
compared with the known photochemical consequences of each flash.
The results were analyzed in terms of models that specified (a) whether
one or two tethered QBr molecules were associated with each channel
and (b) whether channel opening required that one or two tethered QBr
molecules have the trans configuration. Each scheme predicts a different
relation between the fraction of molecules in the trans configuration and
the fraction of active receptors. The conclusion was that each channel’s
activation is controlled by the configuration of a single tethered QBr
molecule. This result is surprising in view of the considerable evidence
(some of it discussed above) that two reversibly bound agonist molecules
are required to activate a single channel. It may be asked whether this
change in functional stoichiometry is caused (a) by the reduction 
disulfide bonds in preparation for the tethering reactions, or (b) by the
covalent attachment of the agonist molecule. Technical difficulties have
thus far prevented a direct answer to this question.
THE PHOTOISOMERIZABLE "OPEN-CHANNEL BLOCKER," EW-I According
to present concepts, local anesthetic molecules act by prematurely
terminating the open state of ionic channels in nerve membranes (l, 9,
20, 101). Channels open normally, and with normal conductance; but in
the open state there is an additional binding site for the blocking
molecule. The voltage dependence of blockade for charged blockers
suggests that the binding site is within the membrane (2), but it is not yet
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162 LESTER & NERBONNE
known whether this site is (a) directly within the channel, so that the
local anesthetic would act like a plug in a drain, or (b) at an allosteric
site elsewhere on the receptor or channel. Also unclear is whether the
blocking drug approaches its binding site from the aqueous phase (in-
tracellular for sodium channels and extracellular for acetylcholine recep-
tor channels) or from within the membrane; probably the two routes
contribute to varying extents for different blocking molecules.
This model makes the explicit statement that the blocking molecule
reaches its binding site only after the channel opens. Thus one predicts
that blockade ought to proceed as usual even though the blocking
molecule is created after the channel opens. Because the blocking potency
of EW-1 (Figure 1) differs in its two configurations, this molecule
enabled a test of the prediction (64; Figure 2). The experiment employed
the brief pulse of acetylcholine that is released in response to a nerve
impulse in the presynaptic terminals. As outlined above, receptors are
activated nearly synchronously; acetylcholine is then hydrolyzed rapidly
A Presumed single-channel events
normal closing:
sudden creation of open-channel blocker:
Postsynoptic currents recorded in the presence of EW-I:
mA/cm2 .
¯
-6I- \’~
flash
t I
,5 msec
Figure 2
EW-I.
Explanation of an experiment with the light-activated "open-channel blocker",
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LIGHT-FLASH PHARMACOLOGY 163
by acetylcholinesterase, and no more channels open. Thus, the decay
phase has an exponential time course formed by the stochastic closing of
individual receptor channels. During this decay phase, a flash was
delivered to create cis-EW-1, the blocking configuration. The experiment
would be more elegant if it employed single-channel recordings like the
imaginary ones of Figure 2A; but the macroscopic record of Figure 2B
plainly shows that the decay phase was accelerated by the flash. Because
no channels open during the decay phase, the newly created cis-EW-1
molecules must be prematurely terminating open channels, in agreement
with the prediction.
Interestingly, the flash-induced blockade in a given trans-EW-1 solu-
tion is temporarily much greater than the steady-state blockade in a
nearly pure cis-EW-1 solution of equal concentration (64). Most of the
blockade disappears with a time constant of about 300 msec. This
transient block depends on the time since the flash rather than on the
time since the opening of channels. Therefore the transient block should
not be confused with the "open-channel blockade" model’s prediction
that at low agonist concentrations, an open-channel blocker ought to
produce major kinetic changes but no appreciable steady-state blockade
(2). Instead, the temporarily increased blockade probably arises because
EW-1 molecules (a) accumulate at the water-membrane interface with
their hydrophobic azobenzene "tails" in the membrane and (b) are
liberated near channels by a flash (35). Thus EW-1 exhibits an additional
nonspecific interaction with membranes, in violation of constraint No. 7.
This phenomenon could possibly be exploited for information on the
extent of local anesthetic penetration into membranes. Also worthy of
further study is the prediction that channels ought to conduct again if
cis-EW-1 could suddenly be flashed off the binding site.
THE PHOTOISOMERIZABLE COMPETITIVE ANTAGONIST, 2BQ Tubocurarine,
the classical competitive antagonist, is thought to block receptors by
binding to the agonist site, preventing normal activation. 2 Little is known
about the kinetics of antagonist-receptor binding, however. The pioneer-
ing experiments with iontophoretic application yielded an estimate that
the tubocurarine-receptor complex has a lifetime of about 2 sec (33), but
those data were distorted by buffered diffusion within the synaptic cleft,
and more recent experiments suggest a lifetime of several tens of millisec-
onds at the most (10, 29, 30). Further progress in understanding these
lifetimes may come from experiments employing a "concentration jump"
of antagonist during steady activation by agonists.
2Under some conditions tubocurarine acts in a more complicated fashion, probably
because it also exerts "open-channel" blockade (29).
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164 LESTER & NERBONNE
The photoisomerizable competitive antagonist, 2BQ, can be exploited
for such experiments (Figure 1). Dose-response data show that the cis
configuration binds about three times more tightly (dissociation constant,
I.SX l0 -7 M) than the trans isomer (66). The initial experiments with
this compound utilized cis-~ trans photoisomerizations while channels
were activated by photostable agonists such as carbachol and suberyl-
dicholine; and the conductance increased, as expected (66). In all cases
the conductance increase was dominated by a kinetic component with the
rate constant of the agonist-receptor interaction (1-20 reset). Under
some conditions there were slower components as well. These results
indicate that 2BQ molecules can vacate receptors so rapidly (<0.5 msec)
that agonist molecules can bind to receptors and open channels without a
measureable delay. That is, antagonist-receptor kinetics are rapid on the
time scale of channel gating. An ambiguity exists: Does this antagonist-
receptor lifetime refer to the relatively potent cis configuration or to the
looser (and presumably shorter-lived) trans-2BQ-receptor complex? These
issues can be addressed with further experiments, especially ones involv-
ing trans -~ cis photoisomerizations, which have become possible recently
because of improved light-flash technology.
MOLECULAR SCORECARD In general, the light-flash experiments with
nicotinic acetylcholine receptors emphasize the rapid and tight coupling
between events at ligand binding sites and events at the ion channel.
Channel opening, closing, or blocking is detectable within a few micro-
seconds of a flash-induced molecular rearrangement at the agonist bind-
ing site, or even of a "concentration jump" of ligands near receptors.
This rapid temporal coupling probably reflects a close physical coupling
among the polypeptide chains that comprise a single acetylcholine recep-
tor monomer (48, 57, 115).
Granted that the light-flash relaxations begin within no detectable
delay after the photochemical reaction. A more probing question is
whether these relaxations reach completion with the ligand-receptor bind-
ing interaction itself or whether the kinetics are governed by slower
processes such as conformational changes in the receptor protein (72, 73).
Probably all investigators would now agree with the latter hypothesis if it
were stated a bit more generally: Channel activation requires a further
molecular event beyond the mere presence of two agonist molecules at
their binding sites. The rate constant for the further transition, if it can
be estimated from the leveling off in relaxation kinetics at high agonist
concentration (91) or from relaxation kinetics with tethered QBr (65), 
of the order of 1-3 msec-1 at 12°C. According to this view, agonists
(and antagonists, judging from the results with 2BQ) are equilibrating
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LIOHT-FLASH PHARMACOLOGY 165
with their binding sites on a more rapid time scale; how much more rapid
is not yet certain, particularly since the light-flash studies have not yet
revealed a signal associated with iigand binding. However the observed
relaxation rates are already so fast that, for ligands at concentrations of
10 -7 M such as Bis-Q and 2BQ, they make serious demands on the
theory of encounter-limited chemical reactions. Perhaps the ligands in
question are accumulating in high concentrations at the membrane-water
interface (65, 108).
There are two possible exceptions to the picture that light-flash relaxa-
tions are dominated by intramoleeular transitions rather than by binding
and dissociation of agonists. (a) During phase 1, channels are closing 
rapidly (>10 msee-l, even at 10°C) that this may be the actual rate of
cis-Bis-Q dissociation. However, this signal is too rapid for investigation
with available voltage-clamp procedure. (b) Most investigators now feel
that "open-channel blockade" occurs as the blocking molecule actually
enters the channel and binds to a blocking site (2).
One may certainly anticipate further progress in understanding the
link between ligand binding and channel behavior. Technical improve-
ments are possible, and underway, in many of the kinetic experiments
described here. However, it will be equally important to have more
refined structural information on the receptor protein itself. This topic is
under investigation in several laboratories.
Studies on Muscarinic Acetylcholine Receptors
In addition to their effects on nicotinic acetylcholine receptors, all the
compounds shown in Figure 1 also interact with muscarinic acetylcholine
receptors. At concentrations on the order of 10-s M, they block the
response to muscarinic agonists in frog heart. This action has been
analyzed in detail using Bis-Q. In homogenates of frog heart, trans-Bis-Q
blocks the binding of a radiolabeled muscarinic antagonist, [3H]-N-
methylscopolamine, with a dissociation constant of about 4 ~M (79, 80).
In voltage-clamped atrial trabeeulae from frog heart, trans-Bis-Q inhibits
the potassium conductance induced by muscarinic agonists. Dose-
response curves for the agonist carbachol are shifted to the right, suggest-
ing competitive blockade, with a dissociation constant of 5 #M. Both the
binding and dose-response studies show that cis-Bis-Q is about 5-fold
weaker as a muscarinic antagonist.
Light-flash experiments were conducted to measure the relaxations of
potassium conductance in response to "concentration jumps" of a
muscarinic antagonist (79, 80). As expected from the equilibrium data,
trans--, cis and cis-, trans photoisomerizations led, respectively, to in-
creases and decreases of the conductance. Also as expected from previous
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166 LESTER & NERBONNE
studies using iontophoretic application of agonists, these relaxations
contrasted in two ways with those seen at nicotinic receptors. First, they
were much slower, requiring several seconds to reach completion. Second,
they did not follow a simple exponential time course. Instead, both
increases and decreases had an S-shaped waveform, including an initial
delay or period of zero slope. The entire waveform of the relaxation,
including the delay, was well described by the function [1- exp(-kt)]2,
where t is the time since the flash. The rate constant k equaled 3 sec- ~ at
24°C and had a Ql0 of 2 to 2.5. However, within the range of conditions
that allowed quantitative measurements, k did not depend on the nature
of the agonist or on its concentration, on the concentration of Bis-Q, or
on the membrane potential. These data indicate that the response to
muscarinic agonists requires the sequential completion of at least two
steps with roughly equal rates. The data provide little information on the
molecular nature of these rate-limiting steps, except to rule out the
agonist-receptor binding event. Many studies suggest that intracellular
second messengers are involved in the response to muscarinic agonists;
and therefore the experiments described in the next two sections may
prove relevant for studies of muscarinic responses.
NUCLEOTIDES
Nucleotides have been generated by the photolysis of o-nitrobenzyl
phosphate diesters and triesters (Figure 3).
Nucleoside Triphosphates
"Caged ATP" was originally synthesized and named by Kaplan et al
(53). These workers showed that ATP is the only nucleotide formed upon
irradiation. Thus, caged ATP is more useful than the a-unsubstituted
analog; photolysis of the latter compound produces only 25% ATP,
presumably because one of the photoproducts is an aldehyde that reacts
with most of the ATP formed by photolysis (86).
Kaplan et al (53) showed that appreciable ATP could be generated
from caged ATP after only 1 sec exposure to a mercury arc lamp. More
detailed photochemical and information was obtained by McCray et al
(75). Although the nitrobenzyl absorption peak is at 265 nm, the action
spectum for ATP formation coincides with that for fluorescence excita-
tion, with a peak at 315 nm. The efficiency of ATP formation per photon
is decreased by only 50% at 347 nm, allowing for studies with a doubled
ruby laser. This system gave 1% conversion per millijoule of flash,
although absolute quantum yields were not measured. Frequency-doubled
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NH2/
C.H$ 0 0 0I II II II \~,L..~
H C--O--pIO--P--O--P--O ~ .,0,~ 7" ~’N"
I
HO OH
"Coged ATP"
H2C--O-~-O’ OH
O~N~ 0
O-nitrobenzy~ c~MP
Fibre 3 Photolabile sters of nucleotides.
ruby lasers can produce several tens of ~llijoules at tNs wavelength,
thus affording substantial conversion.
McCray et al (75) also obtained ~netic information. Transient inter-
mediates were followed directly with spectral monitoring; proton release
was followed with pH indicators; and ATP formation was followed by
measuring the turbidity decrease upon actomyosin dissociation. WitNn 5
~sec (the temporal resolution of the instruments) after the flash, a proton
is released ~d an aci-Ntro intermediate is formed. TNs ~termediate
decays into ATP in an acid-catalyzed step with a rate const~t of
2.2X 109 [H+] sec -~ at 22~C. Thus at pH 7, ATP is f~rmed with a time
constant of 4.5 msec. The reaction mi~t be faster with suitable sub-
stituents on the benzene ring (112).
Caged ATP has desirable bioche~cal properties. The unphotolyzed
molecule seems to be inactive towed ATPases such as the e~t~ocyte
sodium pump (53), the calcium pump of the sarcoplas~c reficulum (47),
actomyosin (49, 75), and bacte~al Ntrogenase (75). The only photoprod-
ucts are a proton, 2-Ntrosacetophenone (wNch appears to have no
harmful effects), and ATP itself. One can thus look fo~ard to useful
kinetic data in systems that ~e rate-li~ted by ATPases.
The same synthetic techniques would presumably yield phomlyzable
2-nitrobenzyl esters of other mono-, di-, and tNphosphonucleotides, as
well as inorg~ic phosphate (46) and pyrophosphate. In particular,
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168 LESTER & NERBONNE
"caged GTP" could become an important tool for exploring biological
processes thought to be rate-limited by GTPases. Increased GTP hydrol-
ysis accompanies hormonal stimulation of adenylate cyclase in many
tissues (24, 55, 62, 68), and the GTPase step is thought to control the
deactivation of adenylate cyclase (25, 26). There are also several analo-
gies between this adenylate cyclase system and the regulation of a
phosphodiesterase by a GTPase in rod outer segments (41, 69, 88).
Cyclic Nucleotides
Simultaneously with the development of caged ATP, Engels and his
colleagues prepared 2-nitrobenzyl triesters of cyclic nucleotides.
a-Unsubstituted esters were used and the aldehyde photobyproducts had
no apparent toxic effects on the biological test systems. The 2-nitrobenzyl
esters by themselves are not hydrolyzed appreciably by cyclic AMP-
specific phosphodiesterase from beef heart; they are weak inhibitors of
phosphodiesterase at millimolar concentrations (37, 58). At a concentra-
tion of 10 -6 M, the o-nitrobenzyl triester of cAMP had less than 10% of
the activity of cAMP itself in a protein kinase assay, but full activity was
obtained after photolysis (36). These observations indicate that 2-nitro-
benzyl triesters bind slightly, or not at all, to intracellular cyclic nucleo-
tide receptors.
The triesters, if dissolved in 1% dimethyl sulfoxide and applied ex-
tracellularly, readily permeate cell membranes. Within a few minutes
after exposure to the o-nitrobenzyl triester (100 500/~M), the physiologi-
cal effects characteristic of cAMP begin to appear. These include mor-
phological alterations in C6 glioma cells (37), positive inotroprotic effects
in guinea pig heart (58), and spontaneous discharge in Aplysia bag cells
(J. M. Nerbonne, L. K. Kaczmarek, and F. Strumwasser, unpublished).
Evidently the cAMP is being generated in the cytosol from the o-
nitrobenzyl triester. It is unclear whether spontaneous hydrolysis alone
[half-time of 29 h at 35°C in physiological solution (58)] is rapid enough
to account for this reaction; intracellular esterases might accelerate the
breakdown of the triester.
It would be of great interest to monitor physiological responses while
employing light flashes to accelerate (by many orders of magnitude) the
appearance of cyclic nucleotides in the cytosol. The results with caged
ATP suggest that such measurements are feasible, at least from the
photochemical viewpoint. How rapidly will the "concentration-jump" of
cAMP lead to activation of protein kinase, phosphorylation of proteins,
and detectable physiological changes? In the heart, there is a lag of a few
seconds between the stimulation of/3-adrenergic receptors and the posi-
tive chronotropic effect (82, 89). Presumably some of this delay involves
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LIGHT-FLASH PHARMACOLOGY 169
the activation of adenylate cyclase and production of cAMP. The time
course of subsequent events would be measured by the experiments
suggested here.
INORGANIC IONS
Calcium
Normal cells regulate the cytoplasmic concentration of calcium and
hydrogen ions at about 10-7 M. Transient increases above this level
occur when Ca2+ enters the cytoplasm either from the external solution
or from an intracellular compartment. Increased Ca2+ levels activate
muscle contraction, exocytosis, and several enzymes. The intracellular
Ca2+ receptor is troponin C in the case of muscle contraction and the
homologous protein, calmodulin, in many other cases.
In some cells, the intracellular [Ca2+] increase produces a change in
the ionic conductance of a membrane. A calcium-activated K+ conduc-
tance was first noted in erythrocytes (114) and has now been described
for neurons, cardiac muscle, salivary glands, and several other tissues
(76). In recent experiments it was shown that 2+ is act ually act ivating
K+ channels (71, 74). There remain several questions about the site 
Ca2+ action, the kinetics of the membrane response, and the detailed
relation between the local Ca2+ level and the membrane conductance.
Such problems could be approached with a molecule that releases Ca2+
upon absorbing a photon.
A photosensitive chelator might be obtained by incorporating both (a)
a photoisomerizable azobenzene group, to obtain large structural dif-
ferences between cis and trans isomers and (b) several carboxylate
groups, to obtain the Ca chelating activity of EDTA and EGTA (see also
103).
(-OzCHzC)2 N -- R -- N (CH2CO~)2
The compound should have the following characteristics:
1. One isomer must chelate Ca2+ with a dissociation constant not
exceeding the intracellular Ca2+ concentration (10-7-10-6 M). For
the other isomer, the chelation must be much weaker--preferably by
at least tenfold.
2. The compound must discriminate between Ca2+ and Mg2÷, with a
strong preference for Ca2+ --preferably 1000-fold.
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170 LESTER & NERBONNE
3. The compound must fulfill the usual requirements for thermal stabil-
ity of the isomers, speed and efficiency of the photoisomerization,
and lack of complicating pharmacology.
It is not yet known whether the desired characteristics can be achieved.
As a first approach, the usual Ca2+ indicators were investigated for
photolability. Like many azobenzene derivatives, the uncomplexed dye
arsenazo III is transiently photochromic on a millisecond time scale
(54a), presumably because the photo-generated cis configuration reisom-
erizes spontaneously with this time course. However it was not possible
to demonstrate transient absorption changes or transient Ca2+ liberation
from complexes of Ca2+ with arsenazo III, eriochrome black, or o-
cresolphthalein complexone (A. Golob, H. A. Lester, unpublished). The
azo bond itself may participate in the chelation and therefore be stabi-
lized in the trans configuration. Similar negative results were obtained in
attempts to bleach Ca2+-murexide complexes.
In other initial investigations, Blank et al (21) have synthesized 4,4’-
bis(a-iminodiacetic acid) azotoluene, in which R is a simple -CH2-group
para to the azo bond, and tested its ability to chelate Zn2+ ions. The
compound is. photoisomerizable and the cis configuration binds Zn2÷
with an affinity constant of 1.1 × 105 M-1, while binding to the trans
configuration is much weaker. Neither isomer binds Ca2+ more tightly
than about 103 M-1, however (J. M. Nerbonne, unpublished results). 
an effort to obtain a higher Ca affinity, the analog in which R is a
para-ethoxy link was synthesized (Nerbonne, unpublished). This mole-
cule binds Ca2+ with a dissociation constant of about 50/t M in the trans
configuration and much more weakly in the cis configuration. Thus,
progress is being made toward the goal of a light-sensitive Ca~+ chelator.
Protons
In comparison with Ca2+, much less is known about the possible role of
protons as an intracellular messenger. It is clear that many intracellular
buffering processes exchange protons for Ca2÷ ions--calmodulin and
mitochondria are examplesmso that any experimental strategy involving
"Ca concentration jumps" must also control for, and examine, pH-jumps
as well (77).
The difficulties are exemplified in current research on the control of
some aspects of intercellular communication mediated by gap junctions.
Pioneering studies in this field led to the conclusion that local increases
in [Ca2÷ ] caused uncoupling (34, 70, 90). More recent work, however, has
stressed the importance of hydrogen ions. Decreases of pH lead to the
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Structure Name
)~max ,rim
(E, cm/’moJ"~) ~’irrod’ nm
[~ CH2OCOCH3
NO2
CIH 3[~CHOCOCH3
NO2
NO2[~CH2OCOCH3
NO2
o - nitrobenzyl 265 ‘500-‘566
acetate (4800)
I- ( o - nitrophenyl)- 2G5 500-566
elhy~ acetate
2,6-dini’~robenzyl 280 300-366
acetate (5200)
(O..,,,,~,~j.(,._) J. CHzOCOCH3 G-acetatenltr°plper°nyl (4200)‘555
300- 420
0"~’~/~" NO2
CH$O-.~ CH2OCOCH3 ‘5,4- dimethoxy-6 550 ‘500-420
nitrobenzyl acetate (4.500)
CH~O NOz
Figure 4 Compounds synthesized for pH-jump experiments. The column labeled ~’irrad
lists the lowest wavelength that we think will not damage cells and the highest wavelength
where the compound absorbs appreciably.
disappearance of electrical coupling in amphibian and fish embryos (89a,
100, 104, 105) and in mouse pancreas (52). It would therefore be 
interest to compare the time course of uncoupling after spatially and
temporally defined increases of [Ca2+ ] and [H+ ].
With these points in mind, we have synthesized a series of nitrobenzyl
esters that can be photolyzed to yield acetic acid and a (hopefully)
inactive fragment (Figure 4). The unphotolyzed compounds are soluble 
aqueous solution at concentrations up to 10-3 M and, being neutral,
penetrate biological membranes without the need for micro-injection.
These compounds have been employed in preliminary intracellular
"pH-jump" experiments with the gap junctions of Chironomus salivary
glands (J. M. Nerbonne, unpublished). The pH is decreased by a 1 
flash from a flash lamp. This leads to uncoupling on a time scale of
seconds. Control experiments show that these effects are due to the pH
jump rather than to the flashes alone or to the nitroso photoproducts. It
is not yet known whether pH-jump relaxations also occur on the millisec-
ond time scale that characterizes voltage-jump relaxations at gap junc-
tions (45, 99).
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GENERATION OF FLASHES
Flashlamp Systems
Commercially available flashlamp systems do not produce sufficient
intensity for the experiments described in this review. Satisfactory
custom-made systems are based on small "short-arc" flash tubes imaged
with UV-efficient optics (79, 81). The flashes last about 0.5 msec.
Laser Systems
Several types of pulsed lasers produce flashes (duration< 1/zsec) suitable
for the photochemical manipulations. Experiments with photoisomeriz-
able azobenzene derivatives utilize a flashlamp-pumped dye laser opti-
mized for 440 nm (59, 94, 95) or another one optimized for 350 nm (R. 
Sheridan and H. A. Lester, unpublished). Experiments on "caged ATP"
were performed with a doubled ruby laser at 347 nm (75).
CONCLUSIONS
Pharmacological experiments with light flashes are now in various stages
of refinement. Useful kinetic information has already been obtained in
electrophysiological experiments with photoisomerizable cholinergic com-
pounds. In other areas, such as "caged" nucleotides, the appropriate
methods are available but are only now being systematically exploited. In
other areas, such as Ca chelators, we probably still lack the necessary
photosensitive compounds. Time will tell whether the experiments are
focused on the right cells, the right molecules, and the right questions.
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